Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients

Cancer

Volumn 78, Issue 10, 1996, Pages 2119-2126

  Palomares, Melanie R ^a,b   Sayre, James W ^a   Shekar, Kota C ^a,b   Lillington, Linda M ^a,b   Chlebowski, Rowan T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

gender; nonsmall cell long carcinoma; prognosis; weight loss

Indexed keywords

ADULT; AGED; ARTICLE; BODY WEIGHT; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATTERN RECOGNITION; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SEX FACTORS; SURVIVAL RATE; WEIGHT LOSS;

EID: 0029985164     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2119::AID-CNCR12>3.0.CO;2-1     Document Type: Article

References (36)

1. Cancer Statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.
3. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
4. Rapp E, Pater JL, William A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-41.
5. Fukuoka M, Masuda N, Furuse K, Negoro S, Tasada M, Katsui K, et al. A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 1991;9:606-13.
6. Bonomi P, Bale M, Rowland K. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys 1991;20:247-52.
7. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990;8:1402-7.
8. Paesmands M, Sculier JP, Libert P, Buceau G, Dabouis G, Thisiaux J, et al. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995;13:1221-30.
9. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech R, Mason BA, Jose RA, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
10. Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, et al. A prognostic factor risk index in advanced non-small cell lung cancer treated with cisplatin containing combination chemotherapy. Cancer Chemother Pharmacol 1992; 30:1-6.
11. Brown JK. Gender, age, usual weight, and tobacco use as predictors of weight loss in patients with lung cancer. Oncol Nurs Forum 1993;20:466-72.
12. Dixon WJ, Brown MB, Englelman L. BMDP Statistical Software. Berkeley: University of California, 1990.
13. Microsoft Excel 5.0. Redmond, WA: Microsoft Corporation, 1994.
14. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-81.
15. Cox DR, Oakes D. Analysis of survival data. London: Chapman & Hall, 1984.
16. Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995;22(2 Suppl 3):67-72.
17. O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986;4:1604-14.
18. Sorenson J, Badsberg JH, Hansen HH. Response to cytotoxic treatment in inoperable adenocarcinoma of the lung: a multivariate regression analysis in 159 patients. Cancer Res 1989;49:S748-54.
19. Kawahara M, Furuse K, Kodama N. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 1991;68:714-9.
20. Palomares MR, Lillington L, Shekar K, Grosvenor M, Sayre J, Chlebowski RT. Clinical outcome, gender, and weight loss in non-small cell lung cancer. Proc Am Soc Clin Oncol 1996;15:1407.
21. Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population: correlations with primary site, nutritional status, and chemotherapy administration. Cancer 1989; 63:330-4.
22. Chlebowski RT, Grosvenor M, Bulcavage L. Glucose metabolism, nutritional status and prognosis in patients with non-small cell lung cancer. FASEB Proc 1991; 5:3732.
23. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213-5.
24. Sridhar MK. Why do patients with emphysema lose weight? Lancet 1995;345:1190-1.
25. Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss in lung cancer management: a review. Nutrition 1996;12:S43-7.
26. Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to treatment. Cancer Res 1982; 42:2495-8.
27. Recchione C, Galante E, Secreto G. Abnormal hormone levels in lung cancer. Tumor 1983;69:293-6.
28. Taggart DP, Gray CE, Bowman A, Faichney A, Davidson KG. Serum androgens and gonadotrophins in bronchial carcinoma. Respir Med 1993;87:455-60.
29. Aasebo U, Bremnes RM, Aakvaag A, Slordal L. Gonadal endocrine dysfunction in patients with lung cancer: relation to responsiveness to chemotherapy, respiratory function and performance status. J Steroid Biochem Mol Biol 1991;39:375-80.
30. Bols-Pratsch M, Yoan YD, Kenneth UA, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadisum. Lancet 1986;II:943-6.
31. Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992;74:1221-5.
32. Morley JE, Perry M, Kaiser FE, Kraenzle D, Jansen J, Houston K, et al. Effects of testosterone replacement in old hypogonadal males. J Am Geriatr Soc 1993;41:149-52.
33. Osterman J. Androgen replacement therapy. Curr Ther Endocrinol Metab 1994;5:286-91.
34. Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski J, Ponce A, et al. Influence of nandrolone decanoate on weight loss in patients with advanced non-small cell lung cancer. Cancer 1986;58:183-8.
35. Gotary CC, Phillips PH, Cheson BD. Male-female differences on the impact of cancer therapy. Oncology 1993;7:67-74.
36. The Office of Research on Women's Health: Appendix II. Summary. In: Recruitment and retention of women in clinical studies. NIH Publication 1993, No. 95-3756.